$NGNE
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Rachel L. McMinn
CEO
107
Employees
$30.46
Current Price
$309.94M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $300,043.20 | 9,600 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $300,043.20 | 9,600 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 5 | $447,481.82 | 16,338 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 12 | $793,630.08 | 31,980 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$1.28
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$1.25
ActualN/A
Revenue
EstimatedN/A
ActualN/A